(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently ...

Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

The agreement comes just three months after Merck said it would be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate, HS-10535, in a deal worth over $2bn. The company will ...

Merck on Tuesday announced that it has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion. The deal will give the U.S. drugmaker access to an experimental heart disease drug ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. News. News. Academy. ... Merck Reaches ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.